Clinical Research
IDE applications, annual reports, amendments, and IRB submissions are the administrative infrastructure of a clinical investigation. Errors or omissions in these documents delay study start, interrupt enrollment, or generate compliance findings that affect the credibility of the data.
Manage Your Trial SubmissionsIDE Submissions
An IDE application for a significant-risk device investigation requires FDA approval before enrollment begins. Under 21 CFR 812.20, the application must include: the applicant's name and address, a complete investigational plan (including protocol, risk analysis, and monitoring procedures), a description of the device, a description of manufacturing and control procedures, an example of all labeling for the device, informed consent forms, the names and addresses of all investigators, and certification of IRB approval or pending approval where applicable.
FDA reviews IDE applications within 30 days and either approves, disapproves, or places the study on clinical hold. Incomplete or deficient submissions result in additional information requests that restart the review clock. The most common deficiencies in IDE applications we have reviewed involve inadequate risk analysis documentation, a protocol that doesn't include the IDE-required investigational plan elements, and device description sections that don't provide sufficient detail for FDA to assess the significant risk determination. We build IDE applications to FDA's explicit content requirements — not to a generic clinical study template.
Once an IDE is approved, changes to the protocol, device, or study procedures may require FDA approval before implementation. Under 21 CFR 812.35, certain amendments require FDA approval (30-day review), while others may be implemented after 5 days if FDA does not object. Emergency modifications may be implemented immediately with concurrent FDA notification.
The categorization of amendments — whether they require the 30-day review, the 5-day implementation pathway, or emergency notification — is a judgment call with regulatory consequences. Implementing a change that required 30-day approval under the 5-day pathway is a violation. We manage amendment classification and submission timing to keep studies moving without compliance exposure.
21 CFR 812.150(b) requires IDE sponsors to submit annual progress reports within 30 days of the anniversary of the IDE's effective date. Annual reports summarize the investigation's current status, enrollment, any unanticipated adverse device effects (UADEs), protocol deviations, and the status of pending publications or presentations. These reports are not administrative formalities — FDA uses them to monitor active investigations and may request additional information or impose conditions on continued enrollment based on annual report content.
At study completion, a final report under 21 CFR 812.150(b)(10) summarizes the investigation and its results. The final report, combined with the clinical study report (CSR), forms the basis of the clinical section of the 510(k) or PMA submission that follows. We structure final reports and CSRs in parallel so the submission transition is seamless.
Get Started
Regulatory submission delays and compliance gaps in active IDE studies create downstream problems for your PMA or 510(k). We manage the regulatory submission calendar so your study stays in good standing with FDA from first patient through final report.